<DOC>
	<DOC>NCT02576314</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotype 3 infection.</brief_summary>
	<brief_title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
	<criteria>Age equal to or greater than 18 years, with chronic genotype 3 HCV infection; Documented HCV treatmentnaïve or treatmentexperienced subjects who failed previous PEG+RBV regimen; HCV RNA &gt; 10,000 IU/mL at Screening; Screening laboratory values within defined thresholds; Negative pregnancy test at baseline (females of childbearing potential only); Use of two effective contraception methods if female of childbearing potential or sexually active male. Pregnant or nursing female; HIV infection or HBV infection (HBcAb and HBsAg positive); Hematologic or biochemical parameters at Screening outside the protocolspecified requirements; Active or recent history (≤ 1 year) of drug or alcohol abuse; Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>